The first clinical studies have successfully applied actinium-225-labeled PSMA-I&T and PSMA-617 showing significant decrease in tumor burden, even after limited results in the same patients with the same tracers labeled with lutetium-177 [16–18]. The gene discussed is FOLH1; the disease is neoplasm.